Clinical studies reported that long-term treatment with anti-IgE therapies, as an add-on to high dose ICS, improves asthma control in both children and adults, reduces the frequency and severity of exacerbations and allows the reduction of doses of ICS (Baena-Cagnani et al., 2015; Mansur et al., 2017). Here, IGHE is linked to asthma.